Geode Capital Management
ETTX

Geode Capital Management’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

Geode Capital Management’s Portfolio ETTX Stock Details ETTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-180,827
Closed -$397K – 5102
2022
Q2 		$397K Buy
180,827
+44,970
+33% +$89.8K ﹤0.01% 3890
2022
Q1 		$254K Buy
135,857
+32,930
+32% +$59.9K ﹤0.01% 4264
2021
Q4 		$225K Buy
102,927
+9,759
+10% +$26.4K ﹤0.01% 4421
2021
Q3 		$311K Buy
93,168
+12,047
+15% +$32.7K ﹤0.01% 4255
2021
Q2 		$216K Buy
81,121
+28,424
+54% +$64.2K ﹤0.01% 4316
2021
Q1 		$112K Buy
52,697
+26,337
+100% +$74.9K ﹤0.01% 4276
2020
Q4 		$65K Buy
+26,360
New +$51.8K ﹤0.01% 4126

Geode Capital Management's ETTX Position: Q3 2022 in Review

Geode Capital Management sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q3 2022, closing a stake of 180,827 shares — an estimated $397K sold.

Geode Capital Management first reported a position in ETTX in Q4 2020 and held it in 7 quarters. The position peaked at $397K in Q2 2022. 0 funds tracked by Wall St. Rank hold ETTX as of Q3 2022.

  • Geode Capital Management reported no remaining Entasis Therapeutics Holdings Inc. position as of Q3 2022 after selling out during the quarter.
  • Geode Capital Management sold 180,827 Entasis Therapeutics Holdings Inc. shares in Q3 2022, an estimated $397K.
  • Geode Capital Management first reported a position in Entasis Therapeutics Holdings Inc. in Q4 2020 and held it in 7 quarters.
  • Geode Capital Management's Entasis Therapeutics Holdings Inc. position peaked at $397K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q3 2022.

Based on Geode Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.